Almanac 2015:atrial fibrillation research in Heart by Jawad-Ul-Qamar, Muhammad & Kirchhof, Paulus
 
 
Almanac 2015
Jawad Ul Qamar, Muhammad; Kirchhof, Paulus
DOI:
10.1136/heartjnl-2015-307809
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Jawad-Ul-Qamar, M & Kirchhof, P 2016, 'Almanac 2015: atrial fibrillation research in Heart', Heart.
https://doi.org/10.1136/heartjnl-2015-307809
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
Almanac 2015: atrial ﬁbrillation research in Heart
Muhammad Jawad-Ul-Qamar,1,2 Paulus Kirchhof1,2,3,4,5
1Institute of Cardiovascular
Sciences, University of
Birmingham, Birmingham, UK
2SWBH NHS Trust,
Birmingham, UK
3UHB NHS Trust, Birmingham,
UK
4Atrial Fibrillation NETwork
(AFNET), Münster, Germany
5Department of Cardiovascular
Medicine, Hospital of the
University of Münster, Münster,
Germany
Correspondence to
Professor Paulus Kirchhof,
Institute of Cardiovascular
Sciences, Institute for
Biomedical Research, 1st ﬂoor,
Room no. 136, Vincent Drive,
Birmingham B15 2TT, UK;
p.kirchhof@bham.ac.uk,
PKirchhofPA@contacts.bham.
ac.uk
Received 1 October 2015
Revised 26 November 2015
Accepted 26 November 2015
Published Online First
20 January 2016
To cite: Jawad-Ul-
Qamar M, Kirchhof P. Heart
2016;102:573–580.
ABSTRACT
Atrial ﬁbrillation continues to attract interest in the
cardiovascular community and in Heart. Over 60 original
research and review papers published in Heart in 2014–
2015 cover various aspects of atrial ﬁbrillation, from
associated conditions and precipitating factors to new
approaches to management. Here, we provide an
overview of articles on atrial ﬁbrillation published in
Heart in 2014–2015, highlighting new developments,
emerging concepts and novel approaches to treatment.
INTRODUCTION
The 2014–2015 have been active years in atrial ﬁb-
rillation (AF) research. Contributions from Heart
on this subject have been very signiﬁcant and sub-
stantial. The articles reﬂect the diverse nature of
problems that patients with AF and their physicians
are faced with, ranging from factors that allow to
estimate the risk of cardiovascular complications
and novel, hypothesis-generating associations of AF
with biomarkers to insights into the optimal
approach to anticoagulation, rate control and
rhythm control therapy. We summarise some of the
more interesting ﬁndings reported on AF in Heart
in the year 2014 and 2015.
RISK FACTORS FOR DEVELOPING AF AND AF
PROGRESSION
Baseline ECG, heart rate and age
A US-based registry (ORBIT -AF Outcomes Registry
for Better Informed Treatment of Atrial Fibrillation.)
analysed more than 6000 patients for risk of pro-
gression of AF from paroxysmal to persistent to per-
manent.1 It was found that increasing age by 10
(OR 1.16) and presence of AF in ECG at baseline
(OR 2.30) were strong predictors of AF progression.
Meanwhile, decreasing heart rate than 80 (OR 0.84)
was protective against progression of AF.
Ivabradine
An important meta-analysis identiﬁed a small (rela-
tive risk (RR) 1.15) but relevant risk for developing
AF in patients treated with ivabradine.2 This effect
is incidentally observed in the same group of
patients (baseline heart rate >70) that get the
highest beneﬁt from receiving ivabradine in terms of
decreasing hospitalisation. This RR of developing
AF could be attributed to change in the If current
induced by ivabradine, a modiﬁcation of the atrial
resting membrane potential, or due to the potential
proarrhythmic effects of bradycardia. Mechanistic
studies are warranted to identify the mechanisms of
AF induction by ivabradine (ﬁgure 1).
Diastolic dysfunction
Results of subanalysis from Tromsø Study in
Norway showed that severely enlarged atrial size as
a marker for diastolic dysfunction was only echo-
cardiographic marker associated with risk of devel-
oping AF (HR 4.2).3 This was independent of
other mitral valve Doppler indices of diastolic dys-
function. Left atrial (LA) size increases with increas-
ing diastolic dysfunction due to long-term change
in left heart ﬂow dynamics.
Haemodialysis
A hypothesis-generating analysis of a cohort of dialy-
sis patients with an implanted pacemaker or deﬁbril-
lator suggested that the haemodialysis procedure
itself could trigger AF.4 The onset of atrial high-rate
events (AHRE) clusters around the time of dialysis
that can be considered as a proxy measure for AF.
An association between higher exacted volume and
lower dialysate potassium concentration is consid-
ered as triggers of AF. Comparatively, patients receiv-
ing peritoneal dialysis had less episodes of AF. These
ﬁndings are consistent across other studies, which
includes age, gender, coronary artery disease and
atrial dimensions as additional risk for developing
AF in haemodialysis patients (ﬁgure 2).5 6
Exercise
Several papers have assessed the impact of physical
exercise on risk of developing AF.7 8 There was an
interesting Swedish study in more than 44 000
healthy adult men demonstrating a U-shaped rela-
tion between exercise and risk of AF.9 They found
that moderate-to-severe exercise in leisure time or
bicycling/walking for more than 60 min in a day
was associated with a RR of 1.17 and 1.04 of
developing AF later in life. Interestingly, this trend
is seen to reverse in the older age with reduction in
RR with similar levels of exercise. Similar favour-
able trends of exercise are seen for middle-aged
and elderly women.10
It is well established that exercise capacity is
reduced in AF with or without the presence of left
ventricular systolic impairment.11 12 There is a sug-
gestion that paroxysmal atrial ﬁbrillation (PAF)
could add to the interplay between exercise and
inherited conditions such as hypertrophic cardio-
myopathy.13 Patients with PAF had a substantially
lower exercise tolerance, even though they
remained in Sinus Rhythm (SR) during exercise
testing. After adjustment for age, sex and body
mass index, PAF still had an independent RR of
4.65 for reduced exercise tolerance.
No beneﬁt of atrial septal defect closure
A Danish study for adult patients diagnosed with
Atrial septal defect (ASD) shows that ASD closure
gives rise to a higher risk of new AF (HR 8.4) as
compared with age and gender matched comparison
cohort, with a 10 year cumulative incidence of
11%.14 The risk of stroke was higher in patients
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with ASD with (HR 2) or without (HR 2.6) ASD closure, sug-
gesting that AF is not prevented by ASD closure. This observation
suggests that other factors than the altered haemodynamic func-
tion determine AF in patients with ASD. Alternatively, an even
earlier timing of ASD closure may be needed to prevent AF.
Other hypothesis-generating associations with AF
An analysis of Myocardial Ischemia National Audit Project data-
base covering all PCI Percutaneous Coronary Intervention pro-
cedures in England and Wales for the short-term effects of air
pollution on cardiovascular events in England and Wales was
published in 2014.15 This showed an increased risk of hospital
admissions due to AF and arrhythmias and high levels of NO2.
A high content of particulate matter less than 2.5 mm in diam-
eter was associated with increased mortality secondary to AF,
arrhythmia and pulmonary embolism.
An observational study for risk of developing atrial ﬂutter and
ﬁbrillation in patients admitted with pericarditis showed an inci-
dence rate of 4.3% with more than 90% having an episode of
AF in the ﬁrst 24 h.16 All of them reverted to sinus rhythm.
However, there was 35% 3 month recurrence rate for patients
who initially developed AF. The authors advocated for anticoa-
gulation in high-risk patients. No increased risk of pericardial
tamponade with anticoagulant therapy was shown.
BIOMARKERS IN AF
Biomarkers have recently generated a lot of interest in predic-
tion, diagnosis and prognostic risk stratiﬁcation of AF.17–20
Troponin I, natriuretic peptides and norepinephrine levels
An substudy of RE-LY (Randomized Evaluation of Longterm
anticoagulant TherapY) regarding the prognostic value and risk
stratiﬁcation of biomarkers in AF has indicated an interesting
use of cardiac biomarkers.21 They have indicated that serial high
levels of cardiac troponin I (cTnI) and N Terminal-pro Brain
Natriuretic Peptide (NT-proBNP) are associated with high inci-
dence of stroke and systemic embolism (HR 4.54) and vascular
death (HR 8.62). Others have earlier found similar association
between these biomarkers and prognosis in AF.22–25 A Japanese
study showed higher levels of atrial natriuretic peptide, brain
natriuretic peptide and norepinephrine (NE) in persistent versus
PAF.26 Only elevated NE levels were found to have an associ-
ation with sick sinus syndrome (ﬁgure 3).
Liver enzymes
Elevated circulating levels of liver enzymes are found to have mod-
erately strong association with increased AF incidence in a large
prospective community-based cohort study of more than 15 000
subjects.27 The association was linear and strongest for gamma glu-
tamyl transferase (GGT) with doubling of GGT levels leading to
20% increase in AF risk after adjusting for the confounding factors.
The association of AF incidence and aspartate amino transferase
(AST) and to a lesser extent alanine amino transferase (ALT)
showed a U-shaped curve with maximum incidence at the two
extremes. This can be explained by right-sided heart failure leading
to hepatic congestion or non-alcoholic fatty liver disease that
increases the cardiovascular risk due to effect on glucose and lipid
metabolism28–30 Correlation between deranged LFTs and risk of
cardiovascular disease has also been published in a subanalysis from
Framingham heart study.31
Adiponectin
An association as a function of increasing age was seen between
higher circulating adiponectin levels and risk of developing
Figure 1 Forest Plot of RR of atrial ﬁbrillation with ivabradine.2 RR, relative risk.
Figure 2 Onset of atrial ﬁbrillation episodes on relation to start of
haemodialysis.4
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AF.32 This is paradoxical to the contemporary belief that higher
adiponectin levels are cardioprotective. Further work is required
in this ﬁeld to identify a clear association with this novel
biomarker.
EPIDEMIOLOGY AND RISK FACTORS
Increasing incidence of AF in the UK
A large population-based cohort study looked at the discharge
record of 2.2 million individuals aged 45 and above, from UK
Clinical Practice Research Datalink.33 They found more than
91 000 incident AF cases. The incidence of AF has increased
from 5.9/1000 person-years in 2001 to 6.9/1000 person-years
in 2013. The overall incidence in terms of 1000 person-years
increases with increasing age (25.1 for patients between 80–89)
and is also higher for Caucasians (8.1) versus Asians (5.4) and
African Americans (4.6).
Predictive value of the CHADS2 and CHA2DS2Vasc scores for
cardiovascular events in patients without AF
CHADS2 and CHA2DS2Vasc scores have been validated to
predict the risk of stroke in patients with AF.34 35 In a study,
these scores were used to assess risk of new stroke/transient
Figure 3 Study endpoints in relation to combined cardiac biomarker levels and CHADS2 score. Stroke or systemic embolism (A), vascular death (B)
and composite thromboembolic outcome consisting of ischaemic stroke, systemic embolism, myocardial infarction, pulmonary embolism and vascular
death (C).21 cTnI, cardiac troponin. NT-pro BNP, N Terminal-pro Brain Natriuretic Peptide. CHADS2, Stroke score (based on a 1 point each for
Congestive heart failure, Hypertension, Age more than 75, Diabetes mellitus and 2 points for previous Stroke or TIA.)
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ischaemic attack (TIA) in the absence of AF in patients with an
acute coronary syndrome (ACS).36 Both these scores showed a
reasonable association predicted annual risk of stroke/TIA with
an absolute annual incidence of 1% with CHADS2 ≥3 and
CHA2DS2Vasc ≥4. This is in line with the results from another
study by Poci et al37 that found association of CHADSs with
mortality and stroke. Others have shown association of these
score with mortality after stroke, risk of developing new AF and
risk of stroke or death after CABG.38–40
AF and heart failure
AF and heart failure are often ‘vicious twins’, and each condi-
tion can worsen the other. A study in Tanzania showed that AF
attributed to at least 16% cases of clinical heart failure present-
ing to tertiary-care hospital.41 This is an interesting ﬁnding if
compared with the EPOCH (Epidemiology, Practice, Outcomes,
and Costs of Heart Failure) study conducted in the USA in 2004
that compared epidemiological characteristics of hospitalised
patients with heart failure and association of various comorbid-
ities with different ethnicities, which showed AF was prevalent
in 19.7% of African–Americans with heart failure as compared
with 38.3% in Caucasian patients with heart failure.42 The
report illustrates the global impact of AF and heart failure.
AF as a predictor of increased mortality in low-gradient
aortic stenosis
AF was found as independent predictor of mortality (HR 1.74)
in patients with aortic stenosis (AS) in a large single centre
observational study of severe AS treated with medical therapy,
surgical aortic valve replacement or transcatheter aortic valve
implantation.43 In general, the group receiving medical
treatment had the worst prognosis with all-cause mortality of
81% at 3.9 years of follow-up. A study showed AF as a deter-
minant of low-ﬂow state in severe AS (OR 4.17).44 In another
study, patients with severe low-gradient AS, AF was also asso-
ciated with a poor prognosis and increased mortality.45 These
observations highlight the importance to diagnose AF in patients
with AS.
Overall AF prevalence in hospitalised patients
An interesting cross-sectional survey in Belgium on a single day
in a tertiary-care hospital identiﬁed total prevalence of AF at
16.8%.46 The presence of AF was associated with old age,
hypertension and valvular heart disease. Interestingly, only 51%
were appropriately treated with oral anticoagulation.
Prognosis of silent AF after myocardial infarction
An observational study by Stamboul et al shows worse 1 year
prognosis with increased hospital admissions and worsening
heart failure for patients found to have silent AF within 2 days
of admission with acute myocardial infarction (MI).47 It was
previously suggested that silent AF was three times more
common than symptomatic AF after acute MI.48 This highlights
importance of continuous ECG monitoring for all patients with
MI to detect AF.
SCREENING FOR SILENT AF
Early diagnosis of AF is highly desirable to initiate therapy prior
to the ﬁrst complication.49 A review article sheds light on emer-
ging techniques to screen for AF.50 Patient-operated ECG moni-
tors or smartphone sensors may be suitable tools to screen for
AF.51–54 In selected patients, long-term screening with
Figure 4 Changes in LA function after catheter ablation. SR group shows an improvement in LA reservoir function. AF, atrial ﬁbrillation; LA, left
atrial; NS, not signiﬁcant.
Figure 5 Patients with atrial ﬁbrillation deemed unsuitable for oral anticoagulation T2 (A) and T2* (B) image at 1.5 T demonstrating conﬂuent
white matter hyperintensities and cerebral microbleeds in a patient with atrial ﬁbrillation with recent transient ischaemic attack T2* images (C/D) at
3.0 T demonstrating an acute lobar haemorrhage and multiple cerebral microbleeds in a patient with atrial ﬁbrillation with suspected cerebral
amyloid angiopathy.59
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implantable loop recorder can generate more AF detection.55
The need for AF-screening programmes, their optimal design
and the best use of therapy (mainly oral anticoagulation) are not
fully understood. Ongoing studies evaluating initiation of antic-
oagulation in patients with atrial high-rate episodes (eg,
ARTESiA or NOAH—AFNET 6) and community screening pro-
grammes such as STROKESTOP56 57 will provide further infor-
mation in future.
IMAGING IN AF
Prognostic factors based on imaging parameters
A review article highlights several adverse prognostic features in
imaging for AF.58 In two-dimensional conventional echocardi-
ography, LA dilatation and left ventricular systolic function was
shown to be associated with increased risk of stroke, heart
failure and all-cause mortality. Mitral stenosis and hypertrophic
cardiomyopathy (HCM) strongly also increases the risk of
stroke in AF. In trans-oesophageal echocardiography (TOE),
spontaneous echo contrast, LA thrombus and complex aortic
valve (AV) plaque predict increased risk of systemic thrombo-
embolism and stroke. In cardiac MRI (CMRI), favourable para-
meters were associated with decreased risk of stroke (OR 0.2).
Moreover, LA conduit function as measured by CMRI was an
important measure of success after catheter ablation (ﬁgure 4).
Brain MRI to tailor anticoagulation therapy
Another review article looked into the value of brain MRI
imaging to tailor anticoagulation therapy.59 It was found that
silent brain infarction is commonly seen in patients with
AF.60 61 This is found to be dependent on the age of patient
and on the type of AF. Presence of cerebral microbleeds (CMB),
which are frequently found in patients with AF without prior
stroke, should be taken as a risk for intracranial bleeding on
anticoagulation. However, large studies are needed to conﬁrm
this observation. Number and location of CMB is affected by
CHADS2 and CHA2DS2Vasc scores. This is mostly due to effect
of vascular risk factors (ﬁgure 5).62
Body Surface Potential Mapping and ECG imaging in AF
Use of ECG imaging, a novel ﬁbrillation imaging modality using
surface ECG combined with cardiac CT/MRI for the atrial
anatomy to assess complexity of AF, was also highlighted.63
More recently, Body Surface Potential Mapping has been shown
to identify the high-frequency sources in the atria without an
imaging modality that were previously measured by invasive
methods.64 This can lead to better patient selection before the
actual ablation procedure based on the prediction of response to
AF ablation therapy.
ANTICOAGULATION FOR STROKE PREVENTION
Which antithrombotic therapy: NOACs, vitamin K antagonist,
combination therapy
A large network meta-analysis of 20 studies combining more
than 78 000 patients demonstrated that the new oral anticoagu-
lants performed better in reducing the risk of stroke or venous
embolism.65 Another meta-analysis with more than 100 000
Figure 6 Estimated GFR in patients with and without recurrences at
baseline and follow-up.76 AF, atrial ﬁbrillation.
Figure 7 Temporal trends of imaging
usage before (CT, MRI, TOE) and
during (ICE) ablation.79 ICE,
intracardiac echocardiography.
Jawad-Ul-Qamar M, Kirchhof P. Heart 2016;102:573–580. doi:10.1136/heartjnl-2015-307809 577
Review
group.bmj.com on June 21, 2016 - Published by http://heart.bmj.com/Downloaded from 
patients showed 47% and 64% odds risk reduction of fatal
bleeding with NOAC compared with vitamin K antagonist
(VKA) therapy and low-molecular weight heparin (LMWH).66
It is well established that combined antiplatelet therapy and
anticoagulation increases the risk of bleeding and that such
‘triple therapy’ should be conﬁned to short periods of time in
selected patients with ACS and/or recent PCI.67 68 An analysis
of large European data set identiﬁed a common mistake in
antithrombotic therapy in patients with AF, that is, the continu-
ation of aspirin therapy in patients with stable vascular
disease.69 Far more than half of the patients subjected to com-
bination therapy with aspirin and oral anticoagulation had no
indication for combination therapy, putting them at unnecessary
risk for bleeding.
The TIARA trial in 238 patients, comparing aspirin and antic-
oagulation in a cohort of patients with AF with moderate stroke
risk and ‘favourable’ imaging characteristics on TOE, suggested
that some patients may fare well without anticoagulation.70
They found that in the absence of LA thrombus on TOE,
aspirin was non-inferior to VKA for all-cause mortality, stroke,
ACS and major bleeding. Interestingly, TIA was not included as
a primary end point, and seven patients suffered from TIA in
the aspirin group. This highlights the challenges when consider-
ing individualised anticoagulation therapy in patients at
low-to-moderate stroke risk. The results of this pilot study need
validation by a larger scale trial.
Anticoagulation in atrial ﬂutter
A review article published in 2015, taking into account 52 pub-
lished articles, indicated that atrial ﬂutter renders a higher risk
of thromboembolic complications.71 Imaging in atrial ﬂutter
also reveals high prevalence of spontaneous echo contrast and
thrombus in left atrial appendage (LAA). Within the limitations
of the small published data sets, this analysis underpins the
current practice to offer anticoagulation to ﬂutter patients.
ABLATION FOR AF
Surgical ablation
A meta-analysis summarising the available information on surgi-
cal ablation for AF has been published.72 This extensive and
ﬁrst-of-its-kind meta-analysis suggests that surgical LA ablation
is a safe and effective method of maintaining sinus rhythm for
more than 1 year in patients with AF and undergoing concomi-
tant cardiac surgery as compared with cardiac surgery alone.
NOACs or warfarin in catheter ablation
A meta-analysis of 14 observational data sets compared dabiga-
tran and warfarin for risks of thromboembolic events and major
bleeds.73 There was no signiﬁcant difference found between the
two groups for either of the two end points. However, a numer-
ical difference of more thromboembolic events in dabigatran
group versus warfarin (0.55% dabigatran vs 0.17% warfarin,
RR 1.78, 95% CI 0.66 to 4.80, p=0.26) was seen.
Another meta-analysis of observational studies also showed a
non-signiﬁcant but higher trend of worse neurological outcomes
with dabigatran versus warfarin.74 No signiﬁcant difference
between dabigatran and warfarin was found in another
meta-analysis.75 There is a need for controlled trials of uninter-
rupted anticoagulation regimes in patients with AF ablation.
Change in renal function associated with arrhythmia
recurrence
A German study with a cohort of 783 subjects found an asso-
ciated with AF recurrence and worsening renal function
(GFR).76 It was found that patients with recurrence had worse
GFR on baseline and on follow-up. The higher CHADS2 and
CHA2DS2Vasc scores were associated with worse renal func-
tions. Finally, those patients who had decline in their GFR had
more AF recurrences. This effect was independent of the type
of OAC used. AF is known to decrease renal function.77 This
may be possibly due to embolic phenomenon or haemodynamic
mechanisms related to AF. Ablation and restoration of sinus
rhythm generally improves renal function.78 However, deterior-
ation of renal function may contribute to recurrent AF. Further
studies are clearly needed to validate this novel observation
(ﬁgure 6).
Peri-procedural imaging in catheter ablation
An observational study found an association between peri-
procedural cardiac imaging such as TOE, intracardiac echocardi-
ography (ICE), cardiac CT and MRI, and better outcomes in
patients undergoing catheter ablation for AF.79 They found that
use of preprocedural cardiac CT/MR was associated with a
lower risk of TIA/stroke at 6 months (0.4% vs 0.9%, adjusted
HR 0.46). Use of ICE was found to be associated with higher
risk of bleeding (1.1% vs 0.7%, adjusted HR 1.76), but also
with a lower incidence of repeat ablation (5.7% vs 8.5%,
adjusted HR 0.68). Interestingly, TOE was not found to affect
procedural outcomes. The usefulness of cardiac CT and MRI in
identifying LA thrombus in patients undergoing ablation has
been found in other studies80 81 on top of their beneﬁt in asses-
sing cardiac anatomy and pulmonary vein size and location82–84
and chances of successful outcome (ﬁgure 7).85
AF-RELATED INAPPROPRIATE SHOCKS IN PATIENTS
WITH ICD
It has been known that prolonged ECG monitoring with pace-
makers and CRT-D have high detection rates of atrial high-rate
episodes,86 87 especially those with home monitoring that
decreases the time to detect AHRE.88 Most, but not all of
these episodes reﬂect paroxysmal, often undiagnosed (silent)
AF. In a study of 1404 patients, it was found that AF lasting
for more than 10 min is detected in a quarter of the patients
who received CRT-D.89 Roughly, three-quarters of all inappro-
priate arrhythmia detections were due to AF, with 60 patients
(4% of the total) receiving inappropriate shocks due to AF
(2.69 patients/100 patient-years). Reprogramming of the shock
criteria could have avoided many of these inappropriate
Figure 8 Kaplan–Meier estimation of probability of atrial
ﬁbrillation-related (AF-related) inappropriate shocks.89
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shocks. Another French case report also explained the use of
home monitoring to prevent in appropriate AF-related shocks
(ﬁgure 8).90
In summary, AF remains one of the major topics of research
published in Heart. We learned a lot, but there is a lot more to
ﬁnd out and study to improve outcomes in patients with AF in
future.
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